IRONWOOD PHARMACEUTICALS INC
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
IRWD | NDAQ
Overview
Corporate Details
- ISIN(s):
- US46333X1081
- LEI:
- Country:
- United States of America
- Address:
- 100 SUMMER STREET, SUITE 2300, 2110 BOSTON
- Website:
- https://www.ironwoodpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ironwood Pharmaceuticals Inc. is a gastrointestinal (GI) healthcare company focused on advancing the treatment of GI diseases. As a commercial-stage biotechnology firm, its core activities involve the research, development, and commercialization of innovative therapies for patients with digestive disorders. The company maintains a singular focus on the GI field, leveraging specialized expertise to address unmet medical needs and redefine the standard of care. Its primary commercial product is LINZESS® (linaclotide), a leading prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IRONWOOD PHARMACEUTICALS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IRONWOOD PHARMACEUTICALS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IRONWOOD PHARMACEUTICALS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
